BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Nabriva Therapeutics Initiates Clinical Phase I Trial of Pleuromutilin Antibiotic BC-3781


7/23/2009 1:45:38 PM

Vienna, Austria- July 23 2009- Nabriva Therapeutics today announced the initiation of a clinical Phase I trial for BC-3781, a pleuromutilin antibiotic being developed to treat serious infections including complicated skin and skin structure infections and community-acquired pneumonia. The clinical study is designed to evaluate the safety and tolerability of BC-3781 in humans via intravenous administration.

BC-3781 is highly active against key gram-positive pathogens, including MRSA, and gram-negative pathogens associated with community-acquired pneumonia. Its novel mode of action ensures that BC-3781 overcomes resistance mechanisms affecting all approved classes of antibiotics. In addition it belongs to the first generation of pleuromutilins to combine availability of both oral and i.v. dosage forms.

Dr. David Chiswell, CEO of Nabriva Therapeutics said: “In 2009 Nabriva intends to generate key human data for our two lead pleuromutilin-based antibiotics, BC-3205 and BC-3781. The BC-3205 oral administration clinical trial is already underway and we are delighted now to be also commencing the trial for intravenously administered BC-3781. Of particular note is that this is the first time a pleuromutilin antibiotic has been administered via the intravenous route opening the possibility for pleuromutilin based step-down therapy.”

About Nabriva Therapeutics

Nabriva Therapeutics is a biotechnology company focused on developing a new class of antibiotics for the treatment of serious infections caused by resistant pathogens. The Company’s two systemically available pleuromutilin antibiotics, BC-3205 and BC-3781, are being developed for both oral and IV administration with extensive clinical phase I data becoming available during 2009. In addition, Nabriva Therapeutics’ topical pleuromutilin product candidate, BC-7013, is also in clinical phase I.

Nabriva Therapeutics has a proven track record in world-class medicinal chemistry, clinical expertise, a seasoned management team and solid IP. Nabriva Therapeutics is located in Vienna, Austria.

For more information on Nabriva please visit www.nabriva.com.


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->